PP405 For Hair Loss - Does it Work?

PP405 is a topical small molecule developed by Pelage Pharmaceuticals as a regenerative treatment for androgenetic alopecia, and it has attracted considerable attention because it aims to address hair loss at the level of stem cell biology rather than focusing purely on hormones or circulation.

The company published a press release mid 2025 that caught a lot of peoples attantion with the results of it's trials, see the Pelage Press Release Here. Their phase 2a clinical trial enrolled 78 men and women with pattern hair loss, representing a broad range of skin phototypes and hair textures, and participants applied either PP405 or placebo once daily for four weeks before being followed through to week twelve.

The study met its primary safety endpoint and its secondary pharmacokinetic endpoint, with no systemic absorption of PP405 detected in blood testing, which is clinically significant when evaluating a topical drug intended for long-term use.

Interest has also been amplified by the calibre of financial backing behind the company. Pelage is supported by a high-profile investor syndicate led by GV, formerly known as Google Ventures, which spearheaded the company’s Series A and Series A-1 financing rounds. When a major venture capital firm associated with Alphabet commits substantial funding to a regenerative medicine company, it inevitably increases visibility and credibility in both scientific and financial circles. That level of investment signals that institutional investors see potential in the underlying biology, although investment enthusiasm does not replace the need for robust long-term clinical data.

What ultimately captured attention, however, was the clinical signal. At week eight, which was four weeks after completing treatment, 31% of men with a higher degree of hair loss who received PP405 achieved more than a 20% increase in hair density, whereas none of the placebo participants reached that threshold. In a field where meaningful change often takes many months to observe, that early separation from placebo stands out.

How PP405 works in practical terms

To understand PP405, it is important to recognise that in androgenetic alopecia, hair follicles often do not disappear entirely. In many patients, dormant follicles and stem cells remain within the scalp but have entered a prolonged inactive state due to a combination of age, genetics, hormonal environment, stress and environmental factors.

PP405 is designed to target the metabolic processes that regulate activation and inactivation of hair follicle stem cells. Rather than reducing dihydrotestosterone or blocking androgen receptors, the compound aims to influence cellular energy pathways within the follicular stem cell niche, effectively encouraging dormant follicles to re-enter the growth phase.

In practical terms, this represents a regenerative strategy. Instead of shielding follicles from hormonal damage or simply stimulating already active hairs, PP405 attempts to restart follicles that have “fallen asleep.”

Does PP405 regrow hair or just slow loss

Based on the Phase 2a data, PP405 appears to do more than slow progression, although it is too early to describe it as definitive regeneration.

The press release highlighted that PP405 induced new hair growth from follicles where no visible hair was previously present, which distinguishes it from therapies that primarily thicken existing miniaturised hairs. If validated in larger trials, that finding would support the claim that PP405 is activating dormant follicles rather than merely enhancing growth from already functioning ones.

That said, the treatment period in this study lasted only four weeks, with follow-up to twelve weeks. Long-term durability, sustainability of response and maintenance requirements remain unanswered questions.